Fujimoto Y, Sasaki T, Tsuchida A, Chayama K
First Department of Internal Medicine, Hiroshima University School of Medicine, 1-2-3 Kasumi, Minami-ku, 734-8551, Hiroshima, Japan.
FEBS Lett. 2001 Apr 27;495(3):197-200. doi: 10.1016/s0014-5793(01)02377-8.
We investigated the expression of angiotensin II type 1 receptor (AT1) in pancreatic cancer. Both AT1 mRNA and protein were expressed in human pancreatic cancer tissues and cell lines. Binding assays showed that pancreatic cancer cells have specific binding sites for angiotensin II and that binding could be eliminated by treatment with a selective AT1 antagonist in a dose-dependent fashion. Surprisingly, the growth of cancer cells was significantly suppressed by treatment with antagonist, also in a dose-dependent manner. These observations suggest AT1 plays an important role in pancreatic cancer growth. Furthermore, ligand-induced inhibition of AT1 may be a useful therapeutic strategy.
我们研究了血管紧张素II 1型受体(AT1)在胰腺癌中的表达。AT1 mRNA和蛋白在人胰腺癌组织和细胞系中均有表达。结合试验表明,胰腺癌细胞具有血管紧张素II的特异性结合位点,并且该结合可通过用选择性AT1拮抗剂处理以剂量依赖性方式消除。令人惊讶的是,用拮抗剂处理也以剂量依赖性方式显著抑制了癌细胞的生长。这些观察结果表明AT1在胰腺癌生长中起重要作用。此外,配体诱导的AT1抑制可能是一种有用的治疗策略。